Date: 2015-08-20
Type of information: Distribution agreement
Compound: Sygnis\' portfolio including TruePrime™ products for primer-free whole genome amplification (WGA) as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA
Company: Sygnis (Germany) Nanodigmbio (China)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism: TruePrime™ is the brand name of a revolutionary novel MDA technology and one of the key products in Sygnis’ portfolio. TruePrime ™ is based on the combination of Sygnis proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
SunScript™ RT is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScript™ Reverse Transcriptase will be available in two versions: SunScript™ RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions for use e.g. in clinical diagnostics whereas SunScript™ RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing (NGS) applications, in gene expression profiling and molecular diagnostics.
Disease:
Details: * On August 20, 2015, Sygnis announced that it has signed a distribution agreement with Nanodigmbio Co. Ltd. for the commercialization of Sygnis’ proprietary product portfolio in China. With this agreement, Sygnis grants Nanodigmbio the rights to promote, market and sell all existing as well as future products including the Company’s revolutionary TruePrime™ products for primer-free whole genome amplification (WGA) as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to researchers in molecular biology, oncology and clinical diagnostics in China.
As a leading solution provider, Nanodigmbio is offering a broad portfolio of quality research reagents as well as high-tech instruments in the wide fields of molecular biology, protein research, cell biology and diagnostics to customers all over China.
Financial terms:
Latest news:
